DBV TECHNOLOGIES WKN: A1JWB7 ISIN: FR0010417345 Kürzel: DBV Forum: Aktien Thema: Hauptdiskussion

https://www.globenewswire.com/news-release/2024/12/11/2995750/0/en/DBV-Confirms-Alignment-with-U-S-FDA-on-Accelerated-Approval-Pathway-for-the-Viaskin-Peanut-Patch-in-Toddlers-1-3-Years-Old.html

🚀🚀🚀🚀

Gleich geht's los 1€🚀

Paris schon wieder angehalten zu viele orders 🎢

https://finance.yahoo.com/news/dbv-technologies-announces-first-patient-213000335.html

https://www.google.com/amp/s/m.ca.investing.com/news/dbv-technologies-earnings-missed-by-102-revenue-topped-estimates-2921542%3fampMode=1 DBV Technologies earnings missed by $1.02, revenue topped estimates

DBV Technologies Reports Full Year 2022 Financial Results and Business Update https://www.globenewswire.com/news-release/2023/03/02/2619881/0/en/DBV-Technologies-Reports-Full-Year-2022-Financial-Results-and-Business-Update.html

💃🤩

DBV Technologies gibt bekannt, dass die FDA den teilweisen klinischen Stopp der Phase-3-Zulassungsstudie mit VITESSE aufgehoben hat

DBV Technologies Reports Third Quarter Financial Results and Business Update https://www.globenewswire.com/news-release/2022/11/03/2548369/0/en/DBV-Technologies-Reports-Third-Quarter-Financial-Results-and-Business-Update.html DBV Technologies Reports Third Quarter Financial Results and Business Update • DBV closes Q3 with a cash balance of $213M • DBV continues to practice budget discipline measures; cash used in operating activities decreased more than 35% between the nine months ended September 30, 2021, and 2022 • DBV continues to engage with the U.S. Food and Drug Administration (FDA) regarding the partial clinical hold on the VITESSE Phase 3 clinical study ...

Moin Fee, hat irgendwie gestern keiner mitbekommen!! Grüße ☕️☕️

Rentnergang ☺️🙋‍♀️

🧚‍♀️

🎉